Advertisement

Topics

GenMark Diagnostics Reports Fourth Quarter and Full Year 2016 Results

16:05 EST 28 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Fourth Quarter Revenue Increased 13% Versus Prior Year to $14.9 million Full Year Revenue Grew by 25% to $49.3 million Submitted FDA 510(k) Applications for ePlex Instrument and Respiratory Pathogen Pane...

Other Sources for this Article

GenMark Diagnostics, Inc.
Hany Massarany
President/Chief Executive Officer
760-448-4325

NEXT ARTICLE

More From BioPortfolio on "GenMark Diagnostics Reports Fourth Quarter and Full Year 2016 Results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...